Oxyphenbutazone

Oxyphenbutazone is a nonsteroidal anti-inflammatory drug (NSAID). It was used in the mid-20th century to treat rheumatoid arthritis and gout, but is no longer used in the United States due to severe adverse effects.

History

Oxyphenbutazone was first synthesized in 1946 by the Boots Company in the United Kingdom. It was one of the first NSAIDs, predating the release of ibuprofen by over a decade. It was initially used to treat rheumatoid arthritis and gout, but was later found to have severe adverse effects.

Pharmacology

Oxyphenbutazone is a non-selective NSAID, meaning it inhibits both cyclooxygenase enzymes, COX-1 and COX-2. This results in decreased production of prostaglandins, which are involved in inflammation and pain sensation. However, inhibition of COX-1 can also lead to gastrointestinal side effects.

Adverse effects

The use of oxyphenbutazone has been associated with severe adverse effects, including bone marrow suppression, leukopenia, thrombocytopenia, and agranulocytosis. These effects are believed to be due to the drug's metabolism to a reactive quinone intermediate, which can cause oxidative damage to cells.

Current status

Oxyphenbutazone is no longer used in the United States due to its severe adverse effects. However, it is still used in some countries for the treatment of acute gout, under strict monitoring for adverse effects.

See also

• Nonsteroidal anti-inflammatory drug
• Rheumatoid arthritis
• Gout

Oxyphenbutazone Resources
Latest articles Most recent articles Ongoing trials	Wikipedia

References

External links

• Drugs.com: Oxyphenbutazone
• PubChem: Oxyphenbutazone